UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO
BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA
FROM THE PHASE 3 SELECT-PSA 2 STUDY

a 2021

UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY

MEASE, P.J., A. LERTRATANAKUL, K. PAPP, F. VAN DEN BOSCH, S. TSUJI et. al.

Základní údaje

Originální název

UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY

Autoři

MEASE, P.J., A. LERTRATANAKUL, K. PAPP, F. VAN DEN BOSCH, S. TSUJI, Eva DOKOUPILOVÁ, M. KEISERMAN, X. BU, L. CHEN, R. MCCASKILL, P. ZUEGER, E. MCDEARMON-BLONDELL, A. PANGAN a W. TILLETT

Vydání

2021

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizační jednotka

Farmaceutická fakulta

DOI

http://dx.doi.org/10.1136/annrheumdis-2021-eular.1066

UT WoS

000692629300490

Klíčová slova anglicky

upadacitinib, psoriatic arthritis, Janus kinase inhibitor

Štítky

rivok, ÚFT

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 22. 3. 2022 16:07, JUDr. Sabina Krejčiříková

Anotace

V originále

Upadacitinib (UPA) is an oral Janus kinase inhibitor currently under evaluation for the treatment of psoriatic arthritis (PsA). Previous 24-week results from the SELECT-PsA 2 study in patients with PsA and prior inadequate response to ≥1 biologic disease-modifying antirheumatic drug (bDMARD) demonstrated UPA efficacy with a safety profile consistent with that observed in rheumatoid arthritis.

Citovat

MEASE, P.J., A. LERTRATANAKUL, K. PAPP, F. VAN DEN BOSCH, S. TSUJI, Eva DOKOUPILOVÁ, M. KEISERMAN, X. BU, L. CHEN, R. MCCASKILL, P. ZUEGER, E. MCDEARMON-BLONDELL, A. PANGAN a W. TILLETT. UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY. 2021. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2021-eular.1066.

@proceedings{1841042,
   author = {Mease, P.J. and Lertratanakul, A. and Papp, K. and Van den Bosch, F. and Tsuji, S. and Dokoupilová, Eva and Keiserman, M. and Bu, X. and Chen, L. and Mccaskill, R. and Zueger, P. and McdearmonandBlondell, E. and Pangan, A. and Tillett, W.},
   doi = {http://dx.doi.org/10.1136/annrheumdis-2021-eular.1066},
   keywords = {upadacitinib, psoriatic arthritis, Janus kinase inhibitor},
   language = {eng},
   title = {UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY},
   url = {https://ard.bmj.com/content/80/Suppl_1/312.1},
   year = {2021}
}

TY  - CONF
ID  - 1841042
AU  - Mease, P.J. - Lertratanakul, A. - Papp, K. - Van den Bosch, F. - Tsuji, S. - Dokoupilová, Eva - Keiserman, M. - Bu, X. - Chen, L. - Mccaskill, R. - Zueger, P. - Mcdearmon-Blondell, E. - Pangan, A. - Tillett, W.
PY  - 2021
TI  - UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY
KW  - upadacitinib, psoriatic arthritis, Janus kinase inhibitor
UR  - https://ard.bmj.com/content/80/Suppl_1/312.1
N2  - Upadacitinib (UPA) is an oral Janus kinase inhibitor currently under evaluation for the treatment of psoriatic arthritis (PsA). Previous 24-week results from the SELECT-PsA 2 study in patients with PsA and prior inadequate response to ≥1 biologic disease-modifying antirheumatic drug (bDMARD) demonstrated UPA efficacy with a safety profile consistent with that observed in rheumatoid arthritis.
ER  -

MEASE, P.J., A. LERTRATANAKUL, K. PAPP, F. VAN DEN BOSCH, S. TSUJI, Eva DOKOUPILOVÁ, M. KEISERMAN, X. BU, L. CHEN, R. MCCASKILL, P. ZUEGER, E. MCDEARMON-BLONDELL, A. PANGAN a W. TILLETT. \textit{UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY}. 2021. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2021-eular.1066.

Podrobný výpis o publikaci